Efficacy and safety of PI3K inhibitors combined with fulvestrant for HR+/HER2− advanced breast cancer: a systematic review and meta-analysis

Efficacy and safety of PI3K inhibitors combined with fulvestrant for HR+/HER2− advanced breast cancer: a systematic review and meta-analysis

ObjectivesThis systematic review and meta-analysis aimed to evaluate the efficacy and safety of combination of Phosphatidylinositol 3-kinase (PI3K) inhibitors and fulvestrant in patients with advanced breast cancer (ABC) who are hormone receptor-positive (HR+) and human epidermal growth factor recep...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xuefeng Li, Hongxian Wang, Shuhui Lin, Tianwen Chen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-06-01
Series:	Frontiers in Oncology
Subjects:	PI3K inhibitors advanced breast cancer progression-free survival PIK3CA mutations meta-analysis
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1556978/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Effect and Treatment of PIK3CA Mutations in Breast Cancer: Current Understanding and Future Directions
by: Young-Bin Cho, et al.
Published: (2025-03-01)

Mutational analysis and protein expression of PI3K/AKT pathway in four mucinous cystadenocarcinoma of the breast
by: Yan Zheng, et al.
Published: (2025-05-01)

Characterizing multi‐PIK3CA mutations across cancer types: Toward precision oncology
by: Kohei Nakamura, et al.
Published: (2024-07-01)

The role of PIK3CA mutations in the development of breast cancer (a literature review)
by: A. O. Pryvalova, et al.
Published: (2020-08-01)

Exploring the Inhibitory Efficacy of Resokaempferol and Tectochrysin on PI3Kα Protein by Combining DFT and Molecular Docking against Wild-Type and H1047R Mutant Forms
by: Cristina Paraschiv, et al.
Published: (2024-09-01)

Plinabulin exerts an anti-proliferative effect via the PI3K/AKT/mTOR signaling pathways in glioblastoma
by: Rouxin Wang, et al.
Published: (2025-01-01)

Mutations of the PIK3CA gene in patients with breast cancer in the Krasnoyarsk region
by: A. V. Zyuzyukina, et al.
Published: (2024-07-01)

Uncovering somatic mosaic variants of PIK3CA-related overgrowth disorders – three cases with different clinical presentations
by: M. Tooming, et al.
Published: (2025-01-01)

Predictive and prognostic features of early and locally advanced <i>PIK3CA</i>-mutated luminal HER2-negative breast cancer
by: A. I. Stukan, et al.
Published: (2024-01-01)

PIK3CA gene mutation status associated with poor prognosis of breast cancer: a retrospective cohort study
by: Min Yan, et al.
Published: (2025-02-01)

PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2− breast cancer
by: Eduardo Terán, et al.
Published: (2024-09-01)

PIK3CA mutations in breast cancer with low HER2 / neu expression
by: I. A. Pavlenko, et al.
Published: (2022-12-01)

Safety findings from the phase 1/2 MOSAIC study of miransertib for patients with PIK3CA-related overgrowth spectrum or Proteus syndrome
by: Whitney Eng, et al.
Published: (2025-07-01)

Clinical, genomic, and histopathologic diversity in cerebral cavernous malformations
by: Jian Ren, et al.
Published: (2025-02-01)

PI3K/AKT Pathway and Brain Malformations
by: Gavin B. Rice, et al.
Published: (2015-07-01)

KIFC3 promotes the progression of non–small cell lung cancer cells through the PI3K/Akt pathway
by: Yu Mu, et al.
Published: (2024-11-01)

Association of PIK3CA somatic mutations with clinicopathological parameters in breast cancer
by: Gizem Teoman, et al.
Published: (2024-12-01)

Targeting the phosphatidylinositol-3-kinase (PI3K) and mitogen activated protein kinase (MAPK) signalling pathways to enhance chemoradiotherapy in locally advanced rectal cancer
by: Aoife Carr, et al.
Published: (2025-01-01)

Role and Therapeutic Potential of miR-301b-3p in Regulating the PI3K-AKT Pathway via PIK3CB in Eosinophilic Chronic Rhinosinusitis
by: Shu F, et al.
Published: (2025-07-01)

Exploring Lymphangioma: A Synthesis of the Literature and Clinical Perspectives
by: Nada Bochor, et al.
Published: (2025-02-01)

Embryological cellular origins and hypoxia-mediated mechanisms in PIK3CA-driven refractory vascular malformations
by: Sota Torii, et al.
Published: (2025-04-01)

Oncogenic activation of PIK3CA in cancers: Emerging targeted therapies in precision oncology
by: Yuxiang Wang, et al.
Published: (2025-03-01)

In silico prediction of the action of bromelain on PI3K/Akt signalling pathway to arrest nasopharyngeal cancer oncogenesis by targeting phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha protein
by: Alyaa Syafiqah Shamsuri, et al.
Published: (2024-11-01)

PI3K/Akt in IPF: untangling fibrosis and charting therapies
by: Janki Bhatt, et al.
Published: (2025-03-01)

Regulation of lymphoma in vitro by CLP36 through the PI3K/AKT/CREB signaling pathway
by: Chao Lv, et al.
Published: (2024-12-01)

Therapeutic management of PI3Kα inhibitor-induced hyperglycemia with a novel glucokinase activator: Advancing the Frontier of PI3Kα inhibitor therapy
by: Guanqin Jin, et al.
Published: (2025-06-01)

The Precision-Guided Use of PI3K Pathway Inhibitors for the Treatment of Solid Malignancies
by: Alexa E. Schmitz, et al.
Published: (2025-05-01)

Discovery of a selective PI3Kα inhibitor via structure-based virtual screening for targeted colorectal cancer therapy
by: Hussam Albassam, et al.
Published: (2025-12-01)

The impact of ROR1, BMI-1 expression and <i>PIK3CA</i> mutation on the prognosis of luminal breast cancer
by: S. V. Vtorushin, et al.
Published: (2025-05-01)

Combinatorial screen of targeted agents with the PI3K inhibitors inavolisib, alpelisib, duvelisib, and copanlisib in multi-cell type tumor spheroids
by: Thomas S. Dexheimer, et al.
Published: (2025-04-01)

The Emerging Role and Clinical Significance of PI3K-Akt-mTOR in Rhabdomyosarcoma
by: Ilaria Versari, et al.
Published: (2025-02-01)

Anti‐tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL‐302 in neuroblastoma
by: Sofie Mohlin, et al.
Published: (2019-07-01)

In Silico Approach for Identification of PI3K/mTOR Dual Inhibitors for Multiple Myeloma Treatment
by: İlke Maşalacı, et al.
Published: (2023-06-01)

METTL3/IGF2BP2 Promotes the Malignant Progression of Esophageal Cancer by Activating the PIK3CA/AKT Pathway
by: Xinmeng Guo, et al.
Published: (2025-02-01)

Assessments of prostate cancer cell functions highlight differences between a pan‐PI3K/mTOR inhibitor, gedatolisib, and single‐node inhibitors of the PI3K/AKT/mTOR pathway
by: Adrish Sen, et al.
Published: (2025-01-01)

EVALUATION OF PTEN AND PI3K/AKT EXPRESSIONS IN STANOZOLOL-TREATED RAT KIDNEYS
by: Tuğba Kotil, et al.
Published: (2022-01-01)

S100 A16 promotes the progression of osteosarcoma by activating the PI3 K/AKT signaling pathway through ANXA2
by: Ying-Ying Xiang, et al.
Published: (2025-06-01)

NEIL3 promotes the carcinogenesis of prostate cancer by activating PI3K/Akt/mTOR signaling
by: Wei Zhang, et al.
Published: (2025-05-01)

Anti-tumor immune modulation and favorable survival outcomes in uterine corpus endometrial carcinoma: insights from PIK3CA/ARID1A co-mutation analysis
by: Dongmei Han, et al.
Published: (2025-04-01)

Exploring target selectivity in designing and identifying PI3Kα inhibitors for triple negative breast cancer with fragment-based and bioisosteric replacement approach
by: Debojyoti Halder, et al.
Published: (2025-01-01)